Daxor Corporation (NASDAQ:DXR) Short Interest Down 42.2% in July

Key Points

• Daxor Corporation (NASDAQ:DXR) experienced a significant 42.2% decrease in short interest from 10,900 shares to 6,300 shares in July, reflecting a short-interest ratio of only 0.2 days.
• Institutional investor Renaissance Technologies LLC raised its position in Daxor by 87.7%, acquiring an additional 13,000 shares, increasing its holdings to 27,821 shares.
• Daxor's shares opened at $10.60 and have seen a 12-month range between a low of $6.55 and a high of $11.38, indicating fluctuating investor sentiment.

Daxor Corporation (NASDAQ:DXR - ) saw a large drop in short interest in July. As of July 31st, there was short interest totaling 6,300 shares, adropof42.2% from the July 15th total of 10,900 shares. Based on an average daily trading volume, of 26,400 shares, the short-interest ratio is currently 0.2 days. Approximately0.3% of the company's stock are sold short. Approximately0.3% of the company's stock are sold short. Based on an average daily trading volume, of 26,400 shares, the short-interest ratio is currently 0.2 days.

Daxor Trading Down 0.1%

Shares of DXR opened at $10.60 on Monday. The business's fifty day simple moving average is $9.63 and its two-hundred day simple moving average is $8.41. Daxor has a 12 month low of $6.55 and a 12 month high of $11.38.

Hedge Funds Weigh In On Daxor

An institutional investor recently raised its position in Daxor stock. Renaissance Technologies LLC raised its holdings in shares of Daxor Corporation (NASDAQ:DXR - Free Report) by 87.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,821 shares of the company's stock after acquiring an additional 13,000 shares during the quarter. Renaissance Technologies LLC owned approximately 0.57% of Daxor worth $214,000 as of its most recent SEC filing. 1.34% of the stock is currently owned by institutional investors.

Daxor Company Profile

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.